pharmaceutical investing RYBREVANT FASPRO plus LAZCLUZE® with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
pharmaceutical investing Johnson & Johnson's RYBREVANT® plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
pharmaceutical investing Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
pharmaceutical investing Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
pharmaceutical investing Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
pharmaceutical investing FDA approves IMAAVY® as first-ever treatment for warm autoimmune hemolytic anemia , representing a landmark advancement for patients
pharmaceutical investing Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
pharmaceutical investing Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
pharmaceutical investing Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
pharmaceutical investing Johnson & Johnson's RYBREVANT FASPRO receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
pharmaceutical investing Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
pharmaceutical investing Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
pharmaceutical investing Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
